Halper Sadeh investigates Utz Brands, BioLife Solutions and Northrim BanCorp deal terms
The investor-rights law firm said it is reviewing proposed transactions involving Utz Brands, BioLife Solutions and Northrim BanCorp for whether shareholders are receiving fair financial terms.
Fact Check
The Halper Sadeh GlobeNewswire release directly confirms the firm is reviewing both deals with the exact terms cited: Forte Biosciences' $77/share cash sale to argenx and Safety Insurance's $105/share cash sale to a Mapfre affiliate. Independent authoritative sources (argenx official press release and SAFT 8-K coverage via StockTitan) corroborate the $77 and $105 per share cash deal prices respectively. All claim elements are verified.
Summary
Halper Sadeh LLC said it is investigating proposed sales and mergers involving Utz Brands, BioLife Solutions and Northrim BanCorp to assess whether the transactions provide fair financial terms to shareholders. The law firm said it is examining whether insiders may receive benefits not available to ordinary shareholders in the deals. The release did not provide further transaction terms in the excerpt.
Terms & Concepts
- fair financial terms: Deal pricing and conditions that adequately compensate shareholders in a sale or merger